Neovascular age-related macular degeneration (AMD) is a complex disease that likely involves multiple angiogenic agents that contribute to the development of choroidal neovascularization (CNV). Although inhibition of vascular endothelial growth factor with ranibizumab has demonstrated efficacy and safety in the treatment of neovascular AMD, novel treatments targeting different mechanisms that play a role in CNV development currently are being investigated. Data from these clinical trials will increase our knowledge of the pathogenesis of AMD and likely provide additions to the treatment armamentarium for improving vision and quality of life in patients with AMD. Financial Disclosure(s): Proprietary or commercial disclosure may be found in the CME frontmatter.
ASJC Scopus subject areas